Laboratory Testing Patterns by Day of Hospital Stay for Medical and Surgical Hospitalizations

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S116-S116
Author(s):  
B Brimhall ◽  
M Whitted ◽  
A Windham ◽  
J Fernandez

Abstract Introduction/Objective Studies of laboratory test utilization and costs by specific hospital day of stay (DOS) have yet to be widely published. Evaluation of laboratory test use by DOS would be helpful to better predict laboratory test reduction as hospital length of stay (LOS) is shortened, since testing on the final day of hospitalization is likely to differ from the average daily figures. Methods/Case Report Using an internal cost accounting database, we evaluated laboratory tests and costs by hospital DOS over one year (2017) at a large health system (N=133,139 hospital days). To evaluate changes over the first days of hospitalization, we set day 1 of hospitalization as a baseline and determined subsequent days as a percentage of day 1 figures. We also calculated laboratory variable cost as a percent of aggregate variable costs per DOS. We limited our analysis to the first week of hospitalization. We employed Medicare Severity Diagnosis Related Groups (MSDRG), used by the US Centers for Medicare and Medicaid Services (CMS), to aggregate hospital encounters into medical or surgical hospitalizations using MSDRG grouping methods. Results (if a Case Study enter NA) For medical inpatient stays, average laboratory tests (variable costs) were 10.8 ($74.11) on day 1, 7.7 ($38.53) on day 2, and 5.8 ($23.75) on day 3, with little change over the next four hospital DOS. Laboratory testing, as a percent of day 1 testing, for days 2-7 was: 70.7%, 53.4%, 54.3%, 54.5%, 55.1%, and 54.0%. Laboratory variable costs represented 7.8% of aggregate variable costs on hospital day 1 and declined sequentially over days 2-7: 5.6%, 4.3%, 3.9%, 3.8%, 3.8%, and 3.5%. For surgical hospitalizations, average laboratory tests (variable costs) were 18.2 ($130.02) on day 1, 11.9 ($57.38) on day 2, and 8.4 ($35.32) on day 3. As with medical stays, there was little change over the next four hospital DOS. Laboratory testing, as a percent of day 1 testing, for days 2-7 was: 65.6%, 46.1%, 44.6%, 46.3%, 45.9%, and 44.9%. Laboratory variable costs represented 3.2% of aggregate variable costs on hospital day 1 and remained essentially unchanged over the following days (range 3.3%-3.7%). Conclusion Laboratory variable costs are highest on the first day of hospitalization and decline over subsequent days to flatten by day 3.

2021 ◽  
Vol 156 (Supplement_1) ◽  
pp. S120-S121
Author(s):  
B Brimhall ◽  
M Whitted ◽  
A Windham ◽  
A Podichetty ◽  
S Shifarraw

Abstract Introduction/Objective Comparisons of diagnostic testing across multiple health systems over multiple years are uncommon. Such comparisons would quantify variations in test use between health systems. Methods/Case Report Using the Vizient Clinical Database, we compared clinical laboratory and imaging utilization for hospitalized adult sepsis patients (N = 69,035) over three years (2017-2019) at 19 large academic-affiliated health systems across the United States. We used Medicare Severity Diagnosis Related Groups (MSDRG), employed by the US Centers for Medicare and Medicaid Services (CMS), and identified sepsis patients (MSDRG triplet 870/871/872). We stratified hospitalized sepsis patients by severity of illness (SOI) into high severity (MSDRG 870), moderate severity (MSDRG 871), and low severity (MSDRG 872) groups. SOI further categorizes patients within a diagnostic group, quantifying the extent of comorbid conditions and complications. We measured hospital length of stay (LOS), number of laboratory tests (CPT codes 80000-89999), and number of imaging studies (CPT codes 70000-79999). We divided the number of laboratory tests and radiology studies by mean hospital LOS (in days) to calculate laboratory tests and imaging studies per hospital day. Results (if a Case Study enter NA) Between health systems, lowest and highest values for laboratory and imaging utilization ranged from 50.1 to 141.3 tests per hospitalization and 1.4 to 7.2 studies per hospitalization, respectively. Differences in laboratory tests between health systems persisted after adjusting for SOI with low to high laboratory tests per hospitalization ranging from 127.8 to 405.7, 51.0 to 144.7, and 31.9 to 78.2, for high, moderate, and low SOI groups. Utilization ranges were smaller for imaging studies. After adjusting for hospital LOS, laboratory testing differences between health systems were more pronounced and with low and high laboratory test per day utilization of 6.5 to 24.3, 6.1 to 18.5, and 6.0 to 17.1, for high, moderate, and low SOI groups. Differences in radiology studies were not as pronounced after adjusting for LOS. Conclusion There is considerable variation among health systems in laboratory and radiology resource utilization for hospitalized sepsis patients. This variation persists, especially for laboratory testing, after adjusting for SOI and LOS.


2001 ◽  
Vol 40 (04) ◽  
pp. 288-292 ◽  
Author(s):  
K. K. W. Yau ◽  
A. H. Lee

Summary Objectives: To identify factors associated with hospital length of stay (LOS) and to model variations in LOS within Diagnosis Related Groups (DRGs). Methods: A proportional hazards frailty modelling approach is proposed that accounts for patient transfers and the inherent correlation of patients clustered within hospitals. The investigation is based on patient discharge data extracted for a group of obstetrical DRGs. Results: Application of the frailty approach has highlighted several significant factors after adjustment for patient casemix and random hospital effects. In particular, patients admitted for childbirth with private medical insurance coverage have higher risk of prolonged hospitalization compared to public patients. Conclusions: The determination of pertinent factors provides important information to hospital management and clinicians in assessing the risk of prolonged hospitalization. The analysis also enables the comparison of inter-hospital variations across adjacent DRGs.


2020 ◽  
Vol 86 (3) ◽  
pp. 250-255 ◽  
Author(s):  
Matthew D. Spann ◽  
Noah J. Harrison ◽  
Wayne J. English ◽  
Aaron R. Bolduc ◽  
Chetan V. Aher ◽  
...  

Roux-en-Y gastric bypass (RYGB) has been explored as a revisional option to failed paraesophageal hernia (PEH) repair with fundoplication, particularly in patients suffering from obesity. However, few studies have assessed long-term outcomes of RYGB with revisional PEH repairin regard to acid-suppressing medication use. We retrospectively identified 19 patients who underwent revisional PEH repair with RYGB between 2011 and 2018. The median operative time was 232 minutes with a median hospital length of stay of two days. The median length of follow-up was 24 months. Two patients (10.5%) had complications in the first 30 days, and five patients (26.3%) had complications within one year. Of the 12 patients on preoperative acid suppression, 6 (50%) were either off medication or on reduced dose at 12 months. The median BMI decrease was 14.4 kg/m2 at 12 months and did not change significantly afterward. Although rates of acid-suppression medication use did not change overall after revisional PEH repair with RYGB, patients experienced successful long-term management of morbid obesity and sustained weight loss. Revisional PEH repair with RYGB is a safe and effective option, with a complication rate comparable with the reported rates after revisional foregut procedures such as revisional Nissen fundoplication.


2021 ◽  
Vol 66 (3) ◽  
pp. 187-192
Author(s):  
O. O. Ivoylov ◽  
A. G. Kochetov

The basis for calculating the cost price of any product, including laboratory tests, is based on an estimate of direct costs of the production. At present, there are no systematic ideas about the structure of such costs, and approaches to their analysis have not been defined, in the management practice of medical laboratories. The purpose of this work was developing and testing a method for analyzing the structure of direct costs and their allocation bases when calculating the cost of a laboratory test. We analyzed data on the volume of laboratory tests performed in the clinical diagnostic laboratory of the National Medical Research Center of Cardiology, prices for purchased reagents and consumables, depreciation and maintenance costs of equipment, staff salaries. As a result, we proposed a typical component structure of direct costs, established the allocation bases of fixed costs, and determined the ratio of some variable cost components to onе product unit cost. On the basis of these concepts, an algorithm for calculating the total direct laboratory (technological) cost per test has been developed, which makes it possible to simulate the cost structure under conditions of arbitrarily specified variables. During the testing of the algorithm, the values of direct costs and the technological cost per test were calculated for billable (ordered) laboratory tests. Comparison of the economic efficiency of various methods, as well as modeling of changes in the cost depending on the volume of testing and the turn-around time (TAT) has been performed. It can be concluded that the approach to creating the tables of the technological cost per test based on dividing direct costs into variable and fixed costs and structuring them by components and allocation bases is an effective tool for medical laboratory management.


2017 ◽  
Vol 36 (3) ◽  
pp. 238-242
Author(s):  
Natasa Bogavac-Stanojevic ◽  
Zorana Jelic-Ivanovic

SummaryLaboratory testing as a part of laboratoryin vitrodiagnostic (IVD) has become required tool in clinical practice for diagnosing, monitoring and prognosis of diseases, as well as for prediction of treatment response. The number of IVD tests available in laboratory practice has increased over the past decades and is likely to further increase in the future. Consequently, there is growing concern about the overutilization of laboratory tests and rising costs for laboratory testing. It is estimated that IVD accounts for between 1.4 and 2.3% of total healthcare expenditure and less than 5% of total hospital cost (Lewin Group report). These costs are rather low when compared to pharmaceuticals and medical aids which account for 15 and 5%, respectively. On the other hand, IVD tests play an important role in clinical practice, as they influence from 60% to 70% of clinical decision-making. Unfortunately, constant increases in healthcare spending are not directly related to healthcare benefit. Since healthcare resources are limited, health payers are interested whether the benefits of IVD tests are actually worth their cost. Many articles have introduced frameworks to assess the economic value of IVD tests. The most appropriate tool for quantitative assessment of their economic value is cost-effectiveness (CEA) and cost-utility (CUA) analysis. The both analysis determine cost in terms of effectiveness or utilities (combine quantity and quality of life) of new laboratory test against its alternative. On the other hand, some investigators recommended calculation of laboratory test value as product of two ratios: Laboratory test value = (Technical accuracy/Turnaround time) × (Utility/Costs). Recently, some researches used multicriteria decision analysis which allows comparison of diagnostic strategies in terms of benefits, opportunities, costs and risks. All analyses are constructed to identify laboratory test that produce the greatest healthcare benefit with the resources available. Without solid evidence that certain laboratory tests are cost-effective, laboratory services cannot be improved. Consequently, simple policy measures such as cost cutting may be imposed upon many laboratories while patients will have limited access to laboratory service.


2021 ◽  
Author(s):  
Nassim Dehouche ◽  
Sorawit Viravan ◽  
Ubolrat Santawat ◽  
Nungruethai Torsuwan ◽  
Sakuna Taijan ◽  
...  

The typical hospital Length of Stay (LOS) distribution is known to be right-skewed, to considerably vary across Diagnosis Related Groups (DRG), and to contain markedly high values, in significant proportions. These very long stays are often considered outliers, and thin-tailed statistical distributions are assumed. Moreover, modeling is typically performed by Diagnosis Related Group (DRG) and is consequently based on small empirical samples, thus justifying the previous assumption. However, resource consumption and planning occur at the level of medical specialty departments covering multiple DRG, and when considered at this decision-making scale, extreme LOS values represent a significant component of the distribution of LOS (the right tail) that determines many of its statistical properties. Through a study of 46,364 electronic health records over four medical specialty departments (Pediatrics, Obstetrics/Gynecology, Surgery, and Rehabilitation Medicine) in the largest hospital in Thailand (Siriraj Hospital in Bangkok), we show that the distribution of LOS exhibits a tail behavior that is consistent with a subexponential distribution. We analyze some empirical properties of such a distribution that are of relevance to cost and resource planning, notably the concentration of resource consumption among a minority of admissions/patients, an increasing residual LOS, where the longer a patient has been admitted, the longer they would, counter-intuitively, be expected to remain admitted, and a slow convergence of the Law of Large Numbers, making empirical estimates of moments (e.g. mean, variance) unreliable. Consequently, we propose a novel Beta-Geometric model that shows a good fit with observed data and reproduces these empirical properties of LOS. Finally, we use our findings to make practical recommendations regarding the pricing and management of LOS.


1996 ◽  
Vol 1 (2) ◽  
pp. 65-76 ◽  
Author(s):  
Lisa I. Iezzoni ◽  
Michael Shwartz ◽  
Arlene S. Ash ◽  
Yevgenia D. Mackiernan

Objectives: In the USA, the role of patient severity in determining hospital resource use has been questioned since Medicare adopted prospective hospital payment based on diagnosis-related groups (DRGs). Exactly how to measure severity, however, remains unclear. We examined whether assessments of severity-adjusted hospital lengths of stay (LOS) varied when different measures were used for severity adjustment Methods: The complete study sample included 18 016 patients receiving medical treatment for pneumonia at 105 acute care hospitals. We studied 11 severity measures, nine based on patient demographic and diagnosis and procedure code information and two derived from clinical findings from the medical record. For each severity measure, LOS was regressed on patient age, sex, DRG, and severity score. Analyses were performed on trimmed and untrimmed data. Trimming eliminated cases with LOS more than three standard deviations from the mean on a log scale. Results: The trimmed data set contained 17 976 admissions with a mean (S.D.) LOS of 8.9 (6.1) days. Average LOS ranged from 5.0–11.8 days among the 105 hospitals. Using trimmed data, the 11 severity measures produced Rsquared values ranging from 0.098–0.169 for explaining LOS for individual patients. Across all severity measures, predicted average hospital LOS varied much less than the observed LOS, with predicted mean hospital LOS ranging from about 8.4–9.8 days. Discussion: No severity measure explained the two-fold differences among hospitals in average LOS. Other patient characteristics, practice patterns, or institutional factors may cause the wide differences across hospitals in LOS.


Author(s):  
Alexander R Cain ◽  
Derek N Bremmer ◽  
Dustin R Carr ◽  
Carley Buchanan ◽  
Max Jacobs ◽  
...  

Abstract Background Preliminary data suggest that the effectiveness of dalbavancin may be similar to current standard of care (SoC) treatment options for osteomyelitis with an advantageous dosing schedule. Methods This was a retrospective, observational cohort study of adult patients diagnosed with osteomyelitis. Patients were matched 1:2 to dalbavancin (administered as 2 doses separated by 1 week) or SoC treatment for osteomyelitis according to Charlson Comorbidity Index, site of infection, and causative pathogen. The primary objective was to determine the incidence of treatment failure after a one-year follow-up period. Secondary objectives included hospital length of stay (LOS), infection-related one-year readmission rates, and treatment-related adverse events. Results A total of 132 patients received dalbavancin (n = 42) or SoC (n = 90). Baseline characteristics, including the rates of surgical intervention, were similar between the two treatment groups. Treatment failure was similar between those who received dalbavancin and SoC (21.4% vs 23.3%, p = 0.81). Patients who received dalbavancin had a shorter hospital LOS (5.2 days vs 7.2 days, p = 0.01). There was no difference in the rates of infection-related readmission between the dalbavancin and the SoC group (31% vs 31.1%, p = 0.99). There were numerically fewer adverse events in the dalbavancin group compared to the SoC group (21.4% vs 36.7%, p = 0.08). Peripherally inserted central catheter line related complications were reported in 17.8% of patients in the SoC group. Conclusions Dalbavancin administered as a two-dose regimen is a safe and effective option for the treatment of osteomyelitis.


2016 ◽  
Vol 11 (5) ◽  
pp. 2986-2987
Author(s):  
Georgios I. Tagarakis ◽  
Costas Dikeos ◽  
Nikolaos Tsilimingas ◽  
Charalampos Tsairidis ◽  
Fani Tsolaki ◽  
...  

Aim. To evaluate the Greek Diagnosis Related Groups(DRG's)system in regard to the procedure of total hip arthroplasty. Methods. In a tertiary university orthopedics department implementing clinical protocols we recruited 75 consecutive patients planned to undergototal hip arthroplasty. Indicators of quality and performance were rates of mortality, pulmonary embolism, trauma dehiscence, disarticulation and readmission. Results. All rates of performance were excellent and equal to zero. The mean length of stay was almost identical to the one predicted by the Greek DRG's. Conclusions. Clinical protocols are connected with good clinical results. The predicted by the Greek DRG's hospital length of stay for total hip arthroplasty lies within pragmatic limits. 


Sign in / Sign up

Export Citation Format

Share Document